Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Concord Healthcare Group Co., Ltd. Class H ( (HK:2453) ) has provided an update.
Concord Healthcare Group has announced a planned leadership transition as long-serving executive director Ms. Fu Xiao tenders her resignation upon reaching retirement age, and moves into an advisory role. The company emphasized that Ms. Fu has no disagreement with the board, and expressed formal appreciation for her contributions during her tenure.
The board has nominated company president Jiang Wei as an executive director, subject to shareholder approval at the May 11 annual general meeting. Jiang, who oversees the group’s AI business and key oncology operations, is expected to drive deeper integration of AI in cancer diagnosis and treatment and spearhead overseas expansion, supporting Concord Healthcare’s ambition to strengthen its leading industry position.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
More about Concord Healthcare Group Co., Ltd. Class H
Concord Healthcare Group Co., Ltd. is a China-based medical services provider focused on oncology diagnosis and treatment. The group operates cancer centers, diagnostic imaging businesses, and an AI-driven healthcare technology platform, with an increasing emphasis on integrating clinical resources and data with artificial intelligence and expanding its presence in overseas markets.
Average Trading Volume: 382,715
Technical Sentiment Signal: Sell
Current Market Cap: HK$901.2M
Find detailed analytics on 2453 stock on TipRanks’ Stock Analysis page.